References
Key articles
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41.Full text Abstract
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Perneczky R, Tene O, Attems J, et al. Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. BMC Med. 2016 Nov 3;14(1):162.Full text Abstract
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.Full text
Reference articles
1. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006 Sep;37(9):2220-41.Full text Abstract
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
3. American Psychiatric Association. DSM-5-TR neurocognitive disorders supplement. Updated excerpts for delirium codes major and mild neurocognitive disorders. October 2022.Full text
4. World Health Organization. Dementia. Mar 2023 [internet publication].Full text
5. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Jan;18(1):88-106.Full text Abstract
6. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022 Feb;7(2):e105-25.Full text Abstract
7. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-32. Abstract
8. Braffman BH, Zimmerman RA, Trojnowski JQ, et al. Brain MR: pathologic correlation with gross and histopathology. II. Hyperintense white matter foci in the elderly. AJR Am J Roentgenol. 1988 Sep;151(3):559-66.Full text Abstract
9. De Reuck J, Deramecourt V, Cordonnier C, et al. The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. J Neurol Sci. 2016 Jul 15;366:164-6. Abstract
10. Perneczky R, Tene O, Attems J, et al. Is the time ripe for new diagnostic criteria of cognitive impairment due to cerebrovascular disease? Consensus report of the International Congress on Vascular Dementia working group. BMC Med. 2016 Nov 3;14(1):162.Full text Abstract
11. Bowler JV. Modern concept of vascular cognitive impairment. Br Med Bull. 2007;83:291-305. Abstract
12. Hagnell O, Franck A, Grasbeck A, et al. Vascular dementia in the Lunby study: 1. a prospective, epidemiological study of incidence and risk from 1957-1972. Neuropsychobiology. 1992;26(1-2):43-9. Abstract
13. Gorelick PB, Brody JA, Cohen DC, et al. Risk factors for dementia associated with multiple cerebral infarcts: a case-control analysis in predominantly African-American hospital-based patients. Arch Neurol. 1993 Jul;50(7):714-20. Abstract
14. Mehta KM, Yeo GW. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017 Jan;13(1):72-83. Abstract
15. Bothongo PLK, Jitlal M, Parry E, et al. Dementia risk in a diverse population: a single-region nested case-control study in the East End of London. Lancet Reg Health Eur. 2022 Apr;15:100321.Full text Abstract
16. Brundel M, de Bresser J, van Dillen JJ, et al. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab. 2012 Mar;32(3):425-36. Abstract
17. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019 Jul;18(7):684-96. Abstract
18. El Husseini N, Katzan IL, Rost NS, et al. Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2023 Jun;54(6):e272-91.Full text Abstract
19. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001 Jun 16;322(7300):1447-51.Full text Abstract
20. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999 Dec 10;53(9):1937-42. Abstract
21. UK Health Security Agency. Air pollution: cognitive decline and dementia. Jul 2022 [internet publication].Full text
22. Sipilä PN, Heikkilä N, Lindbohm JV, et al. Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort. Lancet Infect Dis. 2021 Nov;21(11):1557-67.Full text Abstract
23. Vestin E, Boström G, Olsson J, et al. Herpes simplex viral infection doubles the risk of dementia in a contemporary cohort of older adults: a prospective study. J Alzheimers Dis. 2024;97(4):1841-50.Full text Abstract
24. Wallin A, Milos V, Sjogren M, et al. Classification and subtypes of vascular dementia. International Psychogeriatrics. 2003;15 Suppl 1:27-37. Abstract
25. Horowitz DR, Tuhrim S, Weinberger JM, et al. Mechanisms in lacunar infarction. Stroke. 1992 Mar;23(3):325-7. Abstract
26. Bateman GA. Pulse-wave encephalopathy: a comparative study of the hydrodynamics of leukoaraiosis and normal pressure hydrocephalus. Neuroradiology. 2002 Sep;44(9):740-8. Abstract
27. Lee SH, Kim SM, Kim N, et al. Cortico-subcortical distribution of microbleeds is different between hypertension and cerebral amyloid angiopathy. J Neurol Sci. 2007 Jul 15;258(1-2):111-4. Abstract
28. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007 Jun 15;257(1-2):80-7. Abstract
29. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993 Jun;33(6):568-75. Abstract
30. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese American men in Hawaii: the Honolulu-Asia aging study. JAMA. 1996 Sep 25;276(12):955-60. Abstract
31. Whitmer RA, Gunderson EP, Quesenberry CP, et al. Body mass index in midlife and risk of Alzheimer's disease and vascular dementia. Curr Alzheimer Res. 2007 Apr;4(2):103-9. Abstract
32. Ma Y, Ajnakina O, Steptoe A, et al. Higher risk of dementia in english older individuals who are overweight or obese. Int J Epidemiol. 2020 Aug 1;49(4):1353-65.Full text Abstract
33. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996 Apr 27;347(9009):1141-5. Abstract
34. Guo Z, Viitanen M, Fratiglioni L, et al. Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ. 1996 Mar 30;312(7034):805-8.Full text Abstract
35. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-46.Full text Abstract
36. Gupta A, Perdomo S, Billinger S, et al. Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. BMJ Open. 2020 Nov 17;10(11):e038971.Full text Abstract
37. Pohjasvaara T, Erkinjuntti T, Ylikoski R, et al. Clinical determinants of post stroke dementia. Stroke. 1998 Jan;29(1):75-81. Abstract
38. Doney ASF, Bonney W, Jefferson E, et al. Investigating the relationship between type 2 diabetes and dementia using electronic medical records in the GoDARTS bioresource. Diabetes Care. 2019 Oct;42(10):1973-80.Full text Abstract
39. Celis-Morales CA, Franzén S, Eeg-Olofsson K, et al. Type 2 diabetes, glycemic control, and their association with dementia and Its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022 Mar 1;45(3):634-41.Full text Abstract
40. Cholerton B, Baker LD, Montine TJ, et al. Type 2 diabetes, cognition, and dementia in older adults: toward a precision health approach. Diabetes Spectr. 2016 Nov;29(4):210-9.Full text Abstract
41. Moran C, Lacy ME, Whitmer RA, et al. Glycemic control over multiple decades and dementia risk in people with type 2 diabetes. JAMA Neurol. 2023 Jun 1;80(6):597-604.Full text Abstract
42. Wu CY, Iskander C, Wang C, et al. Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care. 2023 Feb 1;46(2):297-304.Full text Abstract
43. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology. 1995 Jun;45(6):1161-8. Abstract
44. Langballe EM, Ask H, Holmen J, et al. Alcohol consumption and risk of dementia up to 27 years later in a large, population-based sample: the HUNT study, Norway. Eur J Epidemiol. 2015 Sep;30(9):1049-56.Full text Abstract
45. Xu W, Wang H, Wan Y, et al. Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017 Jan;32(1):31-42. Abstract
46. Kjaergaard AD, Johannesen BR, Sørensen HT, et al. Kidney disease and risk of dementia: a Danish nationwide cohort study. BMJ Open. 2021 Oct 22;11(10):e052652.Full text Abstract
47. Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022 Dec 21;43(48):4980-90.Full text Abstract
48. Guo J, Liu Y, Jia J, et al. Effects of rhythm-control and rate-control strategies on cognitive function and dementia in atrial fibrillation: a systematic review and meta-analysis. Age Ageing. 2024 Feb 1;53(2):afae009. Abstract
49. Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol. 2017 Oct 1;74(10):1246-54.Full text Abstract
50. Song R, Xu H, Dintica CS, et al. Associations between cardiovascular risk, structural brain changes, and cognitive decline. J Am Coll Cardiol. 2020 May 26;75(20):2525-34.Full text Abstract
51. Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, et al. Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. Eur Heart J. 2020 Nov 1;41(41):4024-33.Full text Abstract
52. Dove A, Guo J, Marseglia A, et al. Cardiometabolic multimorbidity and incident dementia: the Swedish twin registry. Eur Heart J. 2023 Feb 14;44(7):573-82.Full text Abstract
53. Juul Rasmussen I, Frikke-Schmidt R. Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia. Eur Heart J. 2023 Jul 21;44(28):2526-43.Full text Abstract
54. Ben Hassen C, Fayosse A, Landré B, et al. Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study. BMJ. 2022 Feb 2;376:e068005.Full text Abstract
55. Gallaway PJ, Miyake H, Buchowski MS, et al. Physical activity: a viable way to reduce the risks of mild cognitive impairment, Alzheimer's disease, and vascular dementia in older adults. Brain Sci. 2017 Feb 20;7(2):22.Full text Abstract
56. Hansson O, Svensson M, Gustavsson AM, et al. Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. Alzheimers Res Ther. 2019 Oct 20;11(1):87.Full text Abstract
57. Iso-Markku P, Aaltonen S, Kujala UM, et al. Physical activity and cognitive decline among older adults: a systematic review and meta-analysis. JAMA Netw Open. 2024 Feb 5;7(2):e2354285.Full text Abstract
58. Del Pozo Cruz B, Ahmadi M, Naismith SL, et al. Association of daily step count and intensity with incident dementia in 78 430 adults living in the UK. JAMA Neurol. 2022 Oct 1;79(10):1059-63.Full text Abstract
59. Gebhard C, Corpataux N, Gräni C, et al. Lipid-lowering therapy and the risk of dementia: lessons learned from two decades of controversy. Eur Heart J. 2023 Jun 1;44(21):1855-7.Full text
60. Hussain SM, Robb C, Tonkin AM, et al. Association of plasma high-density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy older adults. Lancet Reg Health West Pac. 2024 Feb;43:100963.Full text Abstract
61. Cantuaria ML, Pedersen ER, Waldorff FB, et al. Hearing loss, hearing aid use, and risk of dementia in older adults. JAMA Otolaryngol Head Neck Surg. 2024 Feb 1;150(2):157-64. Abstract
62. Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart J. 2022 Jun 1;43(21):2010-9.Full text Abstract
63. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019 Oct 22;322(16):1589-99.Full text Abstract
64. Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med. 2003 Oct 13;163(18):2219-29.Full text Abstract
65. Hejl AM, Hogh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002 Oct;73(4):390-4.Full text Abstract
66. Alothman D, Card T, Lewis S, et al. Risk of suicide after dementia diagnosis. JAMA Neurol. 2022 Oct 3;79(11):1148-54.Full text Abstract
67. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies; report of the NINDS-AIREN International Workshop. Neurology. 1993 Feb;43(2):250-60. Abstract
68. American College of Radiology. ACR–ACNM–ASNR–SNMMI practice parameter for brain/PET imaging in dementia. 2020 [internet publication].Full text
69. American College of Radiology. ACR appropriateness criteria: dementia. 2019 [internet publication].Full text
70. Skrobot OA, O'Brien J, Black S, et al. The vascular impairment of cognition classification consensus study. Alzheimers Dement. 2017 Jun;13(6):624-33.Full text Abstract
71. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.Full text Abstract
72. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.Full text
73. Williams PS, Rands G, Orrel M, et al. Aspirin for vascular dementia. Cochrane Database Syst Rev. 2000;(4):CD001296.Full text Abstract
74. Writing Committee Members, Joglar JA, Chung MK, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jan 2;83(1):109-279.Full text Abstract
75. Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007 Jan;13(1):37-41. Abstract
76. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007 Sep;6(9):782-92. Abstract
77. Korczyn AD. Drugs for vascular dementia. Lancet Neurol. 2007 Sep;6(9):749-51. Abstract
78. Black SE. Therapeutic issues in vascular dementia: studies, designs and approaches. Can J Neurol Sci. 2007 Mar;34 Suppl 1:S125-30. Abstract
79. Wilkinson D, Róman G, Salloway S, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. Int J Geriatr Psychiatry. 2010 Mar;25(3):305-13. Abstract
80. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;(3):CD003154.Full text Abstract
81. Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306.Full text Abstract
82. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.Full text Abstract
83. Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999 Jan;174:45-50. Abstract
84. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012 Mar 8;366(10):893-903.Full text Abstract
85. Truong C, Recto C, Lafont C, et al. Effect of cholinesterase inhibitors on mortality in patients with dementia: a systematic review of randomized and nonrandomized trials. Neurology. 2022 Nov 14;99(20):e2313-25.Full text Abstract
86. Hanon O, Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci. 2004 Nov 15;226(1-2):71-4. Abstract
87. López Arrieta J, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;(3):CD000147.Full text Abstract
88. Shah K, Qureshi SU, Johnson M, et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother. 2009 Oct;7(5):250-61. Abstract
89. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004034.Full text Abstract
90. Zonneveld TP, Richard E, Vergouwen MD, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2018 Jul 19;(7):CD007858.Full text Abstract
91. Hughes D, Judge C, Murphy R, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020 May 19;323(19):1934-44.Full text Abstract
92. Etminan M, Gill S, Sammii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003 Jun;23(6):726-30. Abstract
93. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005 Nov 8;65(9):1388-94. Abstract
94. McGuinness B, Craig D, Bullock R, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016 Jan 4;(1):CD003160.Full text Abstract
95. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 Oct;43(10):e404-42.Full text Abstract
96. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532-61.Full text Abstract
97. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
98. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12.Full text Abstract
99. Carrion C, Folkvord F, Anastasiadou D, et al. Cognitive therapy for dementia patients: a systematic review. Dement Geriatr Cogn Disord. 2018;46(1-2):1-26.Full text Abstract
100. Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019 Mar 25;(3):CD013069.Full text Abstract
101. Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD005562.Full text Abstract
102. Kudlicka A, Martyr A, Bahar-Fuchs A, et al. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database Syst Rev. 2023 Jun 29;6(6):CD013388.Full text Abstract
103. Leng M, Zhao Y, Wang Z. Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: A systematic review and Bayesian network meta-analysis. Int J Nurs Stud. 2020 Feb;102:103489. Abstract
104. Möhler R, Renom A, Renom H, et al. Personally tailored activities for improving psychosocial outcomes for people with dementia in community settings. Cochrane Database Syst Rev. 2020 Aug 17;(8):CD010515.Full text Abstract
105. Orgeta V, Qazi A, Spector A, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015 Oct;207(4):293-8.Full text Abstract
106. Bell G, Baou CE, Saunders R, et al. Effectiveness of primary care psychological therapy services for the treatment of depression and anxiety in people living with dementia: evidence from national healthcare records in England. EClinicalMedicine. 2022 Oct;52:101692.Full text Abstract
107. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021 Mar 24;372:n532.Full text Abstract
108. Gottesman RF, Lutsey PL, Benveniste H, et al. Impact of sleep disorders and disturbed sleep on brain health: a scientific statement from the American Heart Association. Stroke. 2024 Mar;55(3):e61-76.Full text Abstract
109. Wilfling D, Calo S, Dichter MN, et al. Non-pharmacological interventions for sleep disturbances in people with dementia. Cochrane Database Syst Rev. 2023 Jan 3;1(1):CD011881.Full text Abstract
110. Park JH, Lee SB, Lee JJ, et al. Depression in vascular dementia is quantitively and qualitatively different from depression in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23:67-73. Abstract
111. Dudas R, Malouf R, McCleery J, et al. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018 Aug 31;(8):CD003944.Full text Abstract
112. Rabins PV, Rovner BW, Rummans T, et al. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Focus (Am Psychiatr Publ). 2017 Jan;15(1):110-28.Full text Abstract
113. Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191.Full text Abstract
114. Zivkovic S, Koh CH, Kaza N, et al. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019 Jun 20;19(1):189.Full text Abstract
115. Huang KL, Fang CJ, Hsu CC, et al. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol. 2017 Dec;31(12):1544-55. Abstract
116. Schneider-Thoma J, Efthimiou O, Huhn M, et al. Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiatry. 2018 Aug;5(8):653-63. Abstract
117. Kheirbek RE, Fokar A, Little JT, et al. Association between antipsychotics and all-cause mortality among community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1916-21.Full text Abstract
118. Chien LY, Chu H, Guo JL, et al. Caregiver support groups in patients with dementia: a meta-analysis. Int J Geriatr Psychiatry. 2011 Oct;26(10):1089-98. Abstract
119. Graff MJ, Adang EM, Vernooij-Dassen MJ, et al. Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. BMJ. 2008 Jan 19;336(7636):134-8.Full text Abstract
120. Chiong W, Tsou AY, Simmons Z, et al. Ethical considerations in dementia diagnosis and care: AAN position statement. Neurology. 2021 Jul 13;97(2):80-9.Full text Abstract
121. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.Full text Abstract
122. Davies N, Barrado-Martín Y, Vickerstaff V, et al. Enteral tube feeding for people with severe dementia. Cochrane Database Syst Rev. 2021 Aug 13;(8):CD013503.Full text Abstract
123. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. 2006 Aug 10;355(6):549-59.Full text Abstract
124. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):147-57. Abstract
125. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 Oct;9(10):959-68. Abstract
126. World Health Organization. Risk reduction of cognitive decline and dementia. 2019 [internet publication].Full text
127. Liang CS, Li DJ, Yang FC, et al. Mortality rates in alzheimer's disease and non-alzheimer's dementias: a systematic review and meta-analysis. Lancet Healthy Longev. 2021 Aug;2(8):e479-88.Full text Abstract
128. O'Brien J. Behavioral symptoms in vascular cognitive impairment and vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):133-138. Abstract
129. Verghese J, Lipton RB, Hall CB. Abnormality of gait as a predictor of non-Alzheimer dementia. N Engl J Med. 2002;347:1761-1768. Abstract
130. Ganesh A, Fraser JF, Gordon Perue GL, et al. Endovascular treatment and thrombolysis for acute ischemic stroke in patients with premorbid disability or dementia: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2022 May;53(5):e204-e217.Full text Abstract
131. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Aug;17(8):1297-306.Full text Abstract
132. Vachon M, Veilleux MC, Macoir J. Promoting the maintenance of satisfactory communication: strategies used by caregivers and medical staff with people suffering from Alzheimer's disease. Geriatr Psychol Neuropsychiatr Vieil. 2017 Jun 1;15(2):185-95. Abstract
Use of this content is subject to our disclaimer